Related Experiment Video

Updated: May 12, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Current and future directions for Phase II trials in high-grade glioma

Brian M Alexander1, Eudocia Q Lee, David A Reardon

  • 1Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, 75 Francis Street, ASB1-L2, Boston, MA 02115, USA.

Expert Review of Neurotherapeutics
|April 3, 2013
PubMed

Insights

High-grade glioma (HGG) treatment remains challenging despite advances. Novel targeted therapies and combination strategies show promise for improving outcomes in patients with this aggressive brain tumor.

Area of Science:

  • Neuro-oncology
  • Molecular oncology
  • Translational cancer research

Background:

  • High-grade glioma (HGG) presents a poor prognosis despite standard treatments like surgery, radiation, and chemotherapy.
  • Recent advancements have elucidated key molecular pathways driving gliomagenesis and tumor progression.
  • Targeted therapies aim to exploit these molecular vulnerabilities for improved HGG treatment.

Purpose of the Study:

  • To review the current landscape of novel therapeutic strategies for high-grade glioma.
  • To assess the progress and challenges of targeted agents and combination therapies in HGG clinical trials.
  • To highlight emerging treatment paradigms for this challenging brain malignancy.

Main Methods:

  • Review of recent clinical trial data for novel agents and combination therapies in high-grade glioma.
  • Analysis of the efficacy and limitations of antiangiogenesis agents in HGG.
  • Exploration of ongoing and future therapeutic strategies targeting molecular pathways in HGG.

Main Results:

  • Single-agent trials have yielded modest clinical benefits in HGG.
  • Antiangiogenesis agents showed initial promise but offered only short-lived clinical benefit, with eventual disease progression.
  • Several novel agents, multi-targeted drugs, and combination therapies are currently under investigation in clinical trials.

Conclusions:

  • Despite progress in understanding HGG molecular biology, effective treatments remain elusive.
  • Combination therapies and multi-targeted agents represent a promising direction for future HGG treatment strategies.
  • Continued research and clinical trials are essential to overcome treatment resistance and improve patient outcomes in high-grade glioma.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...